INTERIM REPORT JANUARY – MARCH 2006

.

· Biacore continued to make progress in the first quarter of 2006. Overall sales increased by 19% to SEK 137.9 million (116.0). The higher than anticipated first quarter sales growth was driven by very strong performances in Europe and the Americas where sales increased by 53% and 41% respectively. Sales in Asia-Pacific declined. Excluding the effect of exchange rates, sales grew by 13% in the first three months of 2006. · Operating income for the first quarter increased by 122% to SEK 30.9 million (13.9). This much improved operating performance was the result of the growth in sales, an improved gross margin and cost controls. The operating margin in the first quarter was 22.4% (12.0). · Net income for the first three months of 2006 amounted to SEK 18.9 million (12.0). Diluted earnings per share were SEK 1.93 (1.24). · Biacore still expects sales for the full-year 2006 to increase at approximately the same rate as in 2005. Operating income for the full-year is expected to grow at a faster rate than sales. As usual, the Company's performance will vary between the quarters. The previous forecast stated: “The outlook for 2006 is for Biacore’s sales to increase at approximately the same rate as in 2005 with modest growth in the first quarter. The operating margin for the first half of the year may decline as the Company further expands its sales and marketing infrastructure, yet it is expected to return to historic levels for the full-year 2006. As usual, the Company's performance will vary between the quarters.” For further information please contact: Erik Walldén, President and CEO, Phone +46 (0)702 252 270 Lars-Olov Forslund, CFO, Phone +46 (0)702 252 727 Jan Isoz, Investor Relations, Phone +46 (0)708 10 31 17 Biacore is a global supplier of systems for protein interaction analysis, an area of increasing importance for scientists in the academic, pharmaceutical, biotechnology and diagnostic markets. The Company's systems generate unique data on the interactions between proteins and other molecules, including small molecules such as drug candidates. During research, development and production, these data give insights into protein functionality, elucidate disease mechanisms and play a key role in the critical decisions needed for efficient development and production of therapeutics. Biacore’s products are used in key areas such as antibody characterization, proteomics, lead characterization, immunogenicity, biotherapeutic development and production. The Company offers a range of products to meet specific application needs. Customers include leading life science research centers, all of the leading global pharmaceutical companies, and a large number of companies in the emerging biotechnology sector. Biacore also markets food analysis solutions, providing key manufacturers with a system and ready-to-use kits for the determination of food quality and safety. The company has its own direct sales capability in the world's key markets (United States, Europe, Japan, Australia) and a distribution network in Asia-Pacific. Biacore was founded in 1984 and is listed on the Stockholm Stock Exchange (SSE:BCOR). This report contains certain forward-looking statements which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Accordingly, investors and shareholders are urged not to place undue reliance on these statements.